Wedbush Maintains Neutral on Biogen, Lowers Price Target to $210
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Biogen (NASDAQ:BIIB) and lowers the price target from $215 to $210.
August 02, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Biogen and lowers the price target from $215 to $210. This suggests a cautious outlook on the stock.
The Neutral rating indicates that the analyst does not expect significant movement in the stock price. The slight reduction in the price target from $215 to $210 suggests a modestly more cautious outlook but not a major shift in sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100